EPI 743

Research use only, not for human use.

EPI 743 (Vatiquinone) is an orally bioavailable para-benzoquinone for treatment of inherited mitochondrial diseases, an analogue of the antioxidant ubidecarenone.

EPI 743 (Vatiquinone) is an orally bioavailable para-benzoquinone for treatment of inherited mitochondrial diseases, an analogue of the antioxidant ubidecarenone.Other Indication Phase 3 Clinical.

Ferroptosis is a form of iron- and lipid-dependent regulated cell death associated with glutathione depletion and production of lipid peroxides by lipoxygenase enzymes.EPI-743 prevents RSL3-induced ferroptosis in PCH6 patient fibroblasts with mean EC50 potency values of 17.3-21.8 nM.EPI-743 (37, 111, 333 nM; 24 h) exhibits prevention of BODIPY 581/591 C11 lipid oxidation.EPI-743 (0.1 nM-1 mM; 48 h) potently prevents ferroptosis induced by RSL3 (2 μM), FeC (100 μM), BSO (50 μM).EPI-743 (1 μM, 3 h) is reduced to EPI-743 hydroquinone (EPI-743-HQ) in PCH6 patient fibroblasts, and EPI-743-HQ (0.1-100 μM; 30 min) inhibits human 15-LO enzyme activity with 20% inhibition at 100 μM, and IC50 is 4.4 μM. Cell Viability Assay Cell Line:Primary fibroblasts and B-lymphocytesConcentration:0-1 mMIncubation Time:48 hours Result:Inhibited RSL3-mediated ferroptotic cell death in B-lymphocytes in a dose-dependent manner.Restored viability to levels comparable with untreated cells, indicating complete rescue.

——

Vatiquinone

Others

Other Targets

Other Targets

Other Indications

Other Disease

1213269-98-7

440.668

C29H44O3

>98% (HPLC)

In Vitro:?DMSO : 100 mg/mL (226.93 mM)

O=C1C(CC[C@](C)(O)CC/C=C(C)/CC/C=C(C)/CC/C=C(C)\C)=C(C)C(C(C)=C1C)=O

2-((R,6E,10E)-3-hydroxy-3,7,11,15-tetramethylhexadeca-6,10,14-trien-1-yl)-3,5,6-trimethylcyclohexa-2,5-diene-1,4-dione

(-20℃)

With Ice Pack

≥ 2 years